Innate Pharma

Stéphanie Cornen

Benjamin Rossi

Laurent Gauthier

Nicolai Wagtmann

Carine Paturel

Hélène Sicard

Simon Kollnberger

Stéphanie Zerbib

Nicolaï Wagtmann

The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

KIR3DL2 binding agents

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

Siglec-9-neutralizing antibodies

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer

This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

Growing community of inventors

Marseilles, France

Stéphanie Cornen